The high profile committee guiding the UK PGx Network
Prof Sir Munir Pirmohamed - NHS Chair of Pharmacogenetics, University of Liverpool
Dr Christine McNamee - Network Manager, University of Liverpool
Prof Ann Daly - Professor of Pharmacogenetics, Newcastle University
Prof Chris Chamberlain - VP Expt Medicine and Diagnostics, UCB
Dr Clare Newland - MRC
Prof Doris-Ann Williams - Chief Executive, BIVDA
Prof Ewan Pearson - Professor of Diabetic Medicine, Dundee University
Dr Fiona Carragher - NHS England
Dr Hilary Burton - Director (CEO) PHG foundation, Genomics & Population Health
Prof Joanne Hackett - Genomics England
Dr Kath Mackay - Innovate UK
Dr Krishna Prasad - Clinical Assessor, MHRA
Dr Louise Leong
Mark Bale - Department of Health
Dr Michael Dunn - Head of the Genetic & Mol Sci Funding, Wellcome Trust
Dr Shahid Hanif - Head of Health Data & Outcomes, ABPI
Dr Terry O’Neill - Head of Health KTN
The Pharmacogenetics and Stratified Medicines Network was set up to facilitate access to, or interaction with, the UK’s stratified medicine clinical and research base activity, and support new collaborations and innovation with the industry base.
Terms of Reference
To help define and formulate the remit and role of the UK Pharmacogenetics and Stratified Medicines network
To disseminate information about the network, to encourage membership and promote attendance to events
To advise on the programme for the annual meeting of the network
To advise on how the network can interact and synergise with all UK stakeholders involved in the field of stratified medicine
To identify funding opportunities for UK pharmacogenetics and stratified medicines researchers, including in the EU and US
To advise on the development and content of the network website
To facilitate interaction and engagement across the life science community which researches, develops, evaluates, commissions, and uses stratified medicine.
To further expand the network across Europe, and then on as a global organisation.
To proactively develop policies to strengthen the UK environment, and global standing, for stratified medicine.